Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 14073  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (730 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Subjects and Methods
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed282    
    Printed4    
    Emailed0    
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 5  |  Page : 1265-1268

Cost of Illness of Major Neurocognitive Disorders in India


1 Department of Neurology, KS Hegde Medical Academy, Mangalore, Karnataka, India
2 Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
3 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Date of Submission19-Jul-2021
Date of Decision17-Aug-2021
Date of Acceptance20-Sep-2021
Date of Web Publication30-Oct-2021

Correspondence Address:
Manjari Tripathi
Department of Neurology, Room No 705, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.329606

Rights and Permissions

 » Abstract 


Background: Major neurocognitive disorders (major NCD) predominantly affect the elderly. Major NCD results in significant morbidity and socioeconomic burden.
Objectives: To estimate the individual cost of care of a person with major NCD according to disease severity and component costs.
Methods and Material: Fifty patients of major NCD with primary caregivers attending memory clinic of tertiary care center were included. A detailed questionnaire administered after inclusion provided demographic and clinical information. Caregivers were interviewed about details of care provided. Cognitive function was assessed by Hindi mental state examination (HMSE), and major NCD severity was determined by clinical dementia rating scale (CDR).
Results: The annual cost of care per patient with mild to moderate and severe major MCD was INR 78288 and INR 167808, respectively. Costs increased with increasing severity of the disease. Direct nonmedical costs were significantly higher than direct medical costs in severe major NCD group and vice versa was found in mild to moderate major NCD group.
Conclusion: Increasing population of elderly and prevalence of major NCD suggest an economic burden on caring families and hence the government. Comprehensive health policy toward providing affordable care to people with major NCD is the need of the hour.


Keywords: Cost of care, direct and indirect costs, major neurocognitive disorder
Key Messages: Economic impact of major NCD remains underestimated in our country; by this study, we wish to put light upon the socioeconomic burden of this disease on the family and country.


How to cite this article:
Malapur PU, Kumar N, Khandelwal SK, Tripathi M. Cost of Illness of Major Neurocognitive Disorders in India. Neurol India 2021;69:1265-8

How to cite this URL:
Malapur PU, Kumar N, Khandelwal SK, Tripathi M. Cost of Illness of Major Neurocognitive Disorders in India. Neurol India [serial online] 2021 [cited 2021 Dec 2];69:1265-8. Available from: https://www.neurologyindia.com/text.asp?2021/69/5/1265/329606




Major neurocognitive disorder (Major NCD) is characterized by significant cognitive decline from a previous level of performance in one or more of the six cognitive domains listed in DSM-5.[1] Additionally, deficits in cognition must be sufficient to interfere with a person's independence in activities of daily living. Major NCD affects the elderly with significant morbidity and substantial socioeconomic impact.

According to the World Alzheimer report 2015,[2] estimated crude prevalence rate in total population over 60 years was 5.2%, with over 46.78 million people living with major NCD worldwide. This number is expected to double by 2030. As per Indian Population Census 2011, nearly 104 million people (8.3% of the total population) are beyond 60 years of age. The estimated number of people living with major NCD in India in 2010 and 2015 was 3.7 million and 4.1 million, respectively.[3] Previously published studies from India estimated a prevalence of major NCD ranging from 1.36% to 8.7%.

Major NCD is a chronic disease characterized by relentless progression and mostly of an irreversible nature. Chronicity and lack of cure make major NCD care costly and time-consuming. Three main components of the cost of major NCD care are direct (medical and nonmedical), indirect, and intangible costs. The global costs of major NCD have increased from US$604 billion in 2010 to US$818 billion in 2015. Estimated annual costs per person with major NCD in the southeast Asian region increased by 26.3% from $1601 in the year 2010 to $2021 in the year 2015 (World Alzheimer report 2015).[2]

Healthcare expenses toward major NCD care in India are predominantly borne by families and caregivers. They face the socioeconomic burden of major NCD. Individual and family face economic burden in various forms: loss of income (both individual and care-giver) and increasing out-of-pocket spending (OOPS) due to increasing health care costs. The increasing prevalence of major NCD will result in a greater economic burden on families and society. The economic impact of major NCD has barely been evaluated in India. This study aimed to estimate the individual cost of care according to major NCD severity and component costs of major NCD care.


 » Subjects and Methods Top


This was a cross-sectional study; 50 major NCD patients with primary caregivers were enrolled consecutively from cognitive disorder and memory clinic in Neurosciences Center, All India Institute of Medical Sciences, New Delhi. Patients diagnosed with Alzheimer's disease, vascular or mixed major NCD as per DSM IV criteria, aged >55 years, disease duration of a year or more with availability of key caregiver were included. Patients with other major NCD types, gross sensory impairment interfering with the assessment, prior mental retardation, and without caregiver were excluded. A primary caregiver was defined as a family member residing with the patient for the past ten years at least, providing most of the daily care. The institutional review board approved the study. Written informed consent was signed by caregivers and, when possible, by patients.

Data collection

Patients and caregivers were administered a questionnaire after inclusion into the study. Demographic information consisting of age, gender, marital status, education, and occupational status were collected. Clinical details about the onset, duration of major NCD, comorbidities, and family history were also noted. Revised norms of the KuppuSwamy scale 2012 were applied to assess the socioeconomic status of the patients.[4]

Cognitive function was assessed by Hindi mental state examination,[5] and severity of major NCD was determined by Clinical dementia rating (CDR) scale.[6] Behavioral disturbances were measured using a brief version of the neuropsychiatry inventory (NPI).[7]

Caregivers were interviewed about their relationship to the patient, marital and occupational status, and number of hours of care provided per day. Information about various aspects of direct and indirect costs of care was also retrieved from caregivers. Total cost was arrived at by adding direct and indirect costs. Cost assessment was done for previous six months from the time of inclusion and was averaged to give a monthly cost. Cost pertaining to comorbidities was also recorded.

Direct medical costs included information on consultations, investigations, admission, treatment, and medication costs.

Direct nonmedical costs included travel, accommodation, professional caregiver or hired help, assisted devices, and house modification costs.

Indirect costs were assessed by the human capital method. It included loss of earnings by patients and loss of productivity of caregivers.

Data analysis was done using STATA version 13 for Windows. Quantitative variables with normal distribution were expressed as mean and SD. Mann–Whitney U test was used for comparison of the significant difference between the two groups.


 » Results Top


Fifty major NCD patients with their caregivers were interviewed for the study. Their baseline demographic characteristics are shown in [Table 1]. The mean age of the sample was 68.56 ± 9.52 years, with ages ranging between 55 and 87 years. There was uneven gender distribution, with 60% sample being males. The majority (66%) of subjects were married. Most of the subjects, that is, approximately 64%, were from urban areas. In terms of educational status, 34% were graduates and 28% were illiterate. With respect to occupational status, 38% of patients were homemakers and 36% were retired employees. Analyzing socioeconomic status, the majority (44%) belonged to the upper-middle group followed by 36% from the lower-middle group.
Table 1: Characteristics of study subjects

Click here to view


Clinical corelates

The study population predominantly had Alzheimer's disease (80%), 14% had vascular major NCD, and the rest 6% had mixed major NCD. Twenty (40%) subjects had one or more comorbidities. All 20 patients had hypertension; in addition to that, seven had CAD, one had DM II, and one was diagnosed with colon tumor. Three (6%) subjects had a family history of major NCD.

Cost assessment and comparison

After applying the CDR scale, subjects were divided as having mild, moderate, and severe major NCD. For the purpose of comparison and to reduce the skewness of data due to the small sample size, patients with mild and moderate major NCD were clubbed together to form a group. The other was the severe major NCD group.

The average monthly cost of care of a person with major NCD ranged from INR 6524 to INR 13984 for mild to moderate major NCD group and severe major NCD group, respectively. On analysis (Mann–Whitney U test), the overall cost of care for severe major NCD patients was found to be significantly higher than that for mild to moderate major NCD patients (P = 0.001).

The overall cost of care and its components are as depicted in [Picture 1].



In severe major NCD, DC (INR 12020) was significantly higher than IC (INR 1964) (P = 0.0000). DNM cost (INR 7874) was statistically higher than DM cost (INR 4146) (P = 0.00).

Mild to moderate major NCD group did not show any statistical difference between DC (INR 2113) and IC (INR 4411). DM cost (INR 1400) was significantly higher than DNM cost (INR 713) (P = 0.000).

The mean total cost of care of major NCD patients with comorbidities (INR 9250) was lesser than that of major NCD patients without comorbidities (INR 11420); however, it was not statistically significant (P = 0.797).


 » Discussion Top


This is a cross-sectional observational study carried out in the patient population attending the memory clinic of a tertiary care center. The chief aim was to determine the household cost of managing a person with major NCD, which would provide a clear picture of the economic burden borne by the patient and/or the family.

The cost of illness per patient in the mild to moderate major NCD group and severe major NCD group was INR 6524 per month and INR 13,984 per month, respectively. The monthly expense was significantly higher for those with severe major NCD, suggesting an increase in the cost of care with worsening major NCD. This finding corroborates with earlier studies by Wolstenholme et al.,[8] Leon et al.,[9] Murman et al.,[10] and Zhu et al.[11]

Assuming mean monthly cost to be constant for the next 12 months, estimated annual costs came up to INR 78288 and INR 167808 for mild-moderate and severe major NCD groups, respectively. Wimo et al. (2005)[12] estimated the annual cost of major NCD care in India to be USD 2229 (INR 100327) to USD 5061 (INR 227795) according to the increasing need for informal care. Rao and Bharath[13] estimated the annual cost of care of major NCD in India by a household budget approach. Based on the severity, it ranged from INR 45600 to INR 202450 in urban areas and INR 20300 to INR 66025 in rural areas. They also noted increasing costs with increasing severity of major NCD.

Thomas et al. (2001)[14] and Kapur et al. (2004)[15] conducted research on cost for epilepsy and diabetes, respectively. The estimated annual cost was INR 13,756 for epilepsy and INR 19,914 for diabetes. These estimates were markedly low compared to the annual cost of major NCD care found in our study.[14],[15]

The various component costs and their proportions from our study are mentioned in [Table 2]. In the mild to moderate group, indirect costs formed the biggest fraction of the overall cost. This suggests huge losses incurred by affected individuals and their families due to lack of earning and provision of home care. Another Indian study also noted that nearly two-thirds (60%) of the total cost was attributed to informal care.[13]
Table 2: Component costs and proportion of total costs

Click here to view


In a systematic review on the economic burden of major NCD by Cantarero-Prieto et al.,[16] indirect costs had the greatest impacts, amounting to 65% of total costs in Europe. Wimo et al. concluded that informal care (62.9%) had the greatest contribution to major NCD care costs in low-middle income countries (based on world bank country classification).[12]

Direct medical costs were significantly higher than direct nonmedical costs in our mild to moderate major NCD group, suggesting expenditure associated with establishing the diagnosis in the earlier stage of major NCD (includes consultations, investigations, and frequent visits to the hospital).

In the group with severe major NCD, direct nonmedical costs (56.3%) had a major contribution to total costs of care. Direct social costs (43.1%) were the major factor in major NCD care costs as estimated by Wimo et al. for high-income countries.[12] In our study, direct nonmedical costs were significantly higher than direct medical costs among patients with severe major NCD. It could be due to the increased need for healthcare assistants and institutionalization during this stage of illness.

Major NCD care in subjects without comorbidity was higher than those with comorbidity; however, there was no statistical difference. Our findings contradicted that of Leon et al.,[9] L. Jonsson et al.,[17] Murman et al.,[18] and Akerborg et al.[19] Murman et al.[18] and Akerborg et al.[19] found that comorbidity resulted in significantly higher direct costs and total cost of major NCD care.

Limitations

Our study is a cross-sectional study with an inherent inability to shed light on the lifetime cost of care of major NCD. The sample size is small and inpatients were not included. All subjects were taken from a memory clinic in a tertiary care center, which might not represent the national population. The risk of recall bias cannot be ruled out as all component costs were predominantly reported by a primary caregiver.


 » Conclusion Top


We aimed to evaluate the economic burden faced by the family while caring person with major NCD. An increase in the elderly population and increasing prevalence of major NCD prove to be an enormous economic burden on both government and caring families in our country. A prospective study with a large cohort on the cost of major NCD care would provide insight and enable health policymakers to plan affordable services to people with major NCD.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.  Back to cited text no. 1
    
2.
Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer report 2015—the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International.  Back to cited text no. 2
    
3.
ARDSI (Alzheimer's and Related Disorders Society of India). In: Shaji KS, Jotheeswaran AT, Girish N, Bharath S, Dias A, Pattabiraman M, et al., editors. The Dementia India Report: Prevalence, impact, costs and services for Dementia. New Delhi: ARDSI; 2010.  Back to cited text no. 3
    
4.
Dudala SR. Updated Kuppuswamy's socioeconomic scale for 2012. J NTR Univ Health Sci 2013;2:201-2.  Back to cited text no. 4
  [Full text]  
5.
Ganguli M, Ratcliff G. A Hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in India. Int J Geriatr Psychiatr 1995;10:367-77.  Back to cited text no. 5
    
6.
Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-4.  Back to cited text no. 6
    
7.
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233-9.  Back to cited text no. 7
    
8.
Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002;181:36-42.  Back to cited text no. 8
    
9.
Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: A cross-sectional study. Am J Manag Care 1999;5:867-77.  Back to cited text no. 9
    
10.
Murman DL, Chen Q, Colucci PM, Colenda CC, Gelb DJ, Liang J. Comparison of healthcare utilization and direct costs in three degenerative dementias. Am J Geriatr Psychiatry 2002;10:328-36.  Back to cited text no. 10
    
11.
Zhu CW, Leibman C, McLaughlin T, Zbrozek AS, Scarmeas N, Albert M, et al. Patient dependence and longitudinal changes in costs of care in Alzheimer's disease. Dement Geriatr Cogn Disord 2008;26:416-23.  Back to cited text no. 11
    
12.
Wimo A, Winblad B, Jönsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007;3:81-91.  Back to cited text no. 12
    
13.
Rao GN, Bharath S. Cost of dementia care in India: Delusion or reality? Indian J Public Health 2013;57:71-7.  Back to cited text no. 13
  [Full text]  
14.
Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, et al. Economic burden of epilepsy in India. Epilepsia 2001;42:1052-60.  Back to cited text no. 14
    
15.
Kapur A, Bjork S, Nair J, Kelkar S, Ramachandran A. Socioeconomic determinants of cost of diabetes care in India. Diabetes Voice 2004;43:18-21.  Back to cited text no. 15
    
16.
Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, Juan PS, Cobo CS. The economic cost of dementia: A systematic review. Dementia (London) 2020;19:2637-57.  Back to cited text no. 16
    
17.
Jönsson L, Eriksdotter Jönhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, et al. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:449-59.  Back to cited text no. 17
    
18.
Murman DL, Von Eye A, Sherwood PR, Liang J, Colenda CC. Evaluated need, costs of care, and payer perspective in degenerative dementia patients cared for in the United States. Alzheimer Dis Assoc Disord 2007;21:39-48.  Back to cited text no. 18
    
19.
Åkerborg Ö, Lang A, Wimo A, Sköldunger A, Fratiglioni L, Gaudig M, et al. Cost of dementia and its correlation with dependence. J Aging Health 2016;28:1448-64.  Back to cited text no. 19
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow